The Fremont biotech says its engineered Yarrowia yeast can brew rare cannabinoids in days at 70-90% below conventional costs. The clever part is not cannabis at all - it is a reusable fermentation platform, and the hard part is proving that lab economics survive the factory floor.
Most biofuels get stuck in the same trap: make the alcohol, then spend a fortune pulling it out of the water. A four-person Houston team engineered a yeast whose product simply volatilizes away - and they think that changes the math.
Helaina is a New York-based biotechnology company using precision fermentation to produce human-equivalent bioactive proteins. Its first commercial product, effera, is a human-identical lactoferrin made in yeast that matches the amino acid sequence of the protein found in mother's milk. Founded in 2019 by food scientist Laura Katz, Helaina sells effera as a B2B ingredient to consumer wellness and supplement brands, targeting women's health, gut health, active nutrition and healthy aging. The company has raised roughly $84 million in equity funding, including a $45 million Series B in 2024.